A study that came out on July 20 and was posted online by JAMA Network Open says that only one-fourth of hemp-derived cannabis products with labels that were correct.
The cannabis content and label accuracy of topical cannabinoid products were reviewed, and the medicinal and nontherapeutic claims of these products were quantified by Tory R. Spindle, PhD, of the Johns Hopkins University School of Medicine in Baltimore. 105 products bought from retail stores and internet retailers were included in the analysis.
What is Cannabis Plant?
The cannabis plant yields an oil called cannabidiol (CBD). They call it “miracle medicine.” Advertisements assert that it is completely safe, legal, and effective for treating all illnesses and discomforts of the mind and body. People are eating it under the false impression that it is harmless, although CBD has unfavourable side effects, may affect how other prescriptions work, and may even be contaminated.
As a result of aggressive marketing and false health claims, CBD has seen an increase in consumer demand. Little thought has been paid to the issues that need to be resolved before CBD is widely accepted in the drive to promote it. These issues will be covered in this essay.
Canopy Health Innovations Report
The researchers discovered that of the 89 products that included the total quantity of CBD on the label, 16 products were inaccurately labelled, 52 products were under-labelled, and 21 products were correctly labelled (e.g., had > 10% more CBD than advertised). The median percentage difference between the total amount of CBD in-store products and the amount listed on the label was 21%, versus 10% for online products.
Despite having less than 0.3 per cent THC (the legal limit for hemp), more than one-third of the goods (35%). Four of the 37 THC-containing products were labelled as THC-free, 14 as containing less than 0.3 per cent THC, and 19 had no mention of THC at all. 28 per cent of the items claimed to be medicinal, 14 per cent claimed to be cosmetic, and 47 per cent claimed that the US Food and Drug Administration had not approved them.
The researchers came to the conclusion that “these results point to the need for increased regulatory monitoring of cannabis and hemp products” to make sure the products are of good quality, stop false health claims, and maybe even prevent users from getting side effects they didn’t want.
Financial connections to Canopy Health Innovations were revealed by several writers.